News Focus
News Focus
Post# of 5032349
Next 10
Followers 744
Posts 63585
Boards Moderated 9
Alias Born 10/05/2009

Re: Zardiw post# 4978928

Sunday, 09/15/2024 10:44:04 AM

Sunday, September 15, 2024 10:44:04 AM

Post# of 5032349
The tide has turned for $BIXT now. First come first serve for bottom feeders, Here is why:

$BIXT TA share data was updated, and the OS share count is now down 50%

The Market cap is now down 50% from $14 Million dollars to $7 Million dollars

And they recently scored a HEME-Foundation 10 Million dollar grant (No debt, no share dilution deal)
to fund completion of the $BIXT synthetic oxygen carrier, that has a 5 year shelf life,
and that can be added to blood plasma in emergencies (when there is no time to do tests and blood type tests, and seconds
can me life or death), to ensure the organs, heart and brain get plenty of oxygen.

The $BIXT synthetic oxygen carrier molecule is so small
it can easily by pass blood clots, while hemoglobin is too large to get past the blood clots.

It will be a game changing life saver in operating rooms, emergency rooms and mash casualty disaster events.

All on top of the having the worlds only Galectin inhibitor that is a non-toxic oral pill, that can stop 60+ viruses from infected human cells, and has world wide PCT patent coverage, and has phase III US FDA IND drug trial approval for long haul Covid, has been tested as a skin cream that stops shingles sores, and is ready for a phase III Covid trial in India.

http://www.bixytaninc.com



NEW BIXT snippet -


Hot off the press, clip from the previous interview that had internet issues. 10 Million dollars grant from the Heme Foundation to fund completing the work, Price under a dime still, and 1/2 the OS retired by insiders.

https://www.msn.com/en-us/health/other/covid-map-update-shows-states-with-very-high-viral-activity-in-wastewater/ar-AA1pRaUS?ocid=msedgdhp&pc=U531&cvid=46c28ea7dec94edf957e4bf92b7b5341&ei=45

Covid is not over

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today